<ul><li>Aurobindo Pharma's subsidiary, Aurolife Pharma LLC, received 11 observations from the US FDA following an inspection of its Raleigh plant in North Carolina.</li><li>The inspection took place from March 24 to April 10, 2025.</li><li>Aurobindo Pharma will provide a detailed response to the FDA within the required timeline, addressing each observation with appropriate corrective and preventive measures.</li><li>The company stated that it does not expect this development to have any material impact on current business operations or existing supplies from the facility.</li></ul>

Aurobindo Pharma's US Plant Gets 11 FDA Observations

Discover more